The epithelial-mesenchymal transition (EMT) bestows cancer cells with increased stem cell properties and metastatic potential. To date, multiple extracellular stimuli and transcription factors have been shown to regulate EMT. Many of them are not druggable and therefore it is necessary to identify targets, which can be inhibited using small molecules to prevent metastasis. Recently, we identified the ganglioside GD2 as a novel breast cancer stem cell marker. Moreover, we found that GD3 synthase (GD3S)-an enzyme involved in GD2 biosynthesis-is critical for GD2 production and could serve as a potential druggable target for inhibiting tumor initiation and metastasis. Indeed, there is a small molecule known as triptolide that has been shown to inhibit GD3S function. Accordingly, in this manuscript, we demonstrate that the inhibition of GD3S using small hairpin RNA or triptolide compromises the initiation and maintenance of EMT instigated by various signaling pathways, including Snail, Twist and transforming growth factor-β1 as well as the mesenchymal characteristics of claudin-low breast cancer cell lines (SUM159 and MDA-MB-231). Moreover, GD3S is necessary for wound healing, migration, invasion and stem cell properties in vitro. Most importantly, inhibition of GD3S in vivo prevents metastasis in experimental as well as in spontaneous syngeneic wild-type mouse models. We also demonstrate that the transcription factor FOXC2, a central downstream effector of several EMT pathways, directly regulates GD3S expression by binding to its promoter. In clinical specimens, the expression of GD3S correlates with poor prognosis in triple-negative human breast tumors. Moreover, GD3S expression correlates with activation of the c-Met signaling pathway leading to increased stem cell properties and metastatic competence. Collectively, these findings suggest that the GD3S-c-Met axis could serve as an effective target for the treatment of metastatic breast cancers.
INTRODUCTION
The epithelial-mesenchymal transition (EMT) is a normal developmental process whereby epithelial cells lose their epithelial characteristics, such as cell-cell adhesions, and undergo a marked remodeling of the cytoskeleton that culminates in the acquisition of a motile mesenchymal phenotype. [1] [2] [3] This complex series of morphological changes is accompanied by the downregulation of epithelial markers (for example, E-cadherin) and the upregulation of mesenchymal markers (for example, N-cadherin and vimentin). EMT occurs during embryogenesis as well as in tissue repair, fibrosis and cancer. [4] [5] [6] During cancer progression, the EMT process endows cancer cells with the ability to metastasize. EMT and metastasis are regulated by distinct signaling molecules present in the tumor microenvironment (for example, transforming growth factor-β1 (TGF-β1), Wnt, tumor necrosis factor-α, hepatocyte growth factor and Notch), [7] [8] [9] and a variety of intracellular transcription factors (for example, Snail, Twist and Goosecoid). [10] [11] [12] [13] [14] [15] [16] Cells that undergo EMT also acquire self-renewal capabilities, express stem cell-associated CD44 high CD24 low cell surface markers and become resistant to chemotherapy. [17] [18] [19] [20] [21] [22] We recently found that epithelial cells induced to undergo EMT behave similar to mesenchymal stem/stromal cells. 23 Furthermore, the ganglioside GD2, normally known to be expressed in mesenchymal stem/ stromal cells, is also expressed on the cell surface of breast cancer stem cells (CSCs) and can be used for their isolation. 24 Although suppression of GD3 synthase (GD3S), the rate-limiting enzyme for GD2 biosynthesis, hampers mammosphere formation and stem cell properties, 24 its role in metastasis is not known. Among various signaling pathways, c-Met (hepatocyte growth factor receptor) is frequently deregulated in many cancers, and is known to promote invasion, survival and metastasis. [25] [26] [27] [28] [29] [30] [31] [32] [33] Moreover, GD3S expression has been shown to enhance the proliferation of MDA-MB-231 cells through the activation of c-Met. 34 In this manuscript, we describe that GD3S regulates not only EMT and CSC properties, but also metastasis in vivo. GD3S regulates stem cell function via c-Met and the expression of GD3S is regulated by FOXC2, a transcription factor functioning downstream of several EMT signaling pathways. In addition, we report that GD3S expression is high in EMT/CSC-enriched claudin-low/ triple-negative human breast cancers and that its expression correlates with poor patient survival.
RESULTS
GD3S is necessary for the initiation and maintenance of EMT Earlier, we found that the ganglioside GD2 serves as a marker for breast CSCs and that the enzyme GD3S is essential for GD2 biosynthesis. 24 As CSCs and cells that have undergone EMT share many properties, we investigated whether GD3S is necessary for maintaining the mesenchymal status of human mammary epithelial (HMLE) cells experimentally induced to undergo EMT (HMLE-Snail and HMLE-Twist) as well as established breast cancer cell lines (SUM159 and MDA-MB-231). For this, we used small hairpin RNA (shRNA) to suppress GD3S expression and found that inhibition of GD3S expression substantially altered the morphology of each cell type, causing increased clustering of cells into epithelial-like islands with the establishment of cell-cell contacts and reduced fibroblastic morphology (Figure 1a ). Furthermore, the expression of the mesenchymal markers N-cadherin, fibronectin and vimentin was reduced to varying degrees in the absence of GD3S (Figure 1b ). Likewise, the inhibition of GD3S activity in the aforementioned cells using the small-molecule inhibitor triptolide 35 induced an epithelial-like morphology (Figure 1c ) accompanied by a reduction in the expression of mesenchymal markers (Supplementary Figure 1a ) without changing the rate of cell proliferation ( Supplementary Figure 1b ). In addition, we observed increased expression of the epithelial marker E-cadherin in HMLE-Snail, HMLE-Twist and MDA-MB-231 cells, but not in SUM159 cells (Figure 1b; Supplementary Figure 1a ). Collectively, these findings suggest that GD3S is necessary for the maintenance of mesenchymal properties of both cells induced to undergo EMT, as well as mesenchymal-appearing breast cancer cell lines.
As current evidence suggests that the induction of EMT in tumors can generate new CSCs and/or replenish the existing CSC pool, deterring the mechanisms underlying the initiation of EMT is as important as targeting cells that have already undergone EMT. To examine the potential role of GD3S in the initiation of EMT, we utilized a TGF-β1-inducible model and report that blocking GD3S activity prevented the acquisition of a spindle-like morphology in TGFβ-treated (2 ng/ml) MCF-10A cells (Figures 1d and e; Supplementary Figure 1c ). We observed similar results using the mouse mammary EpH4Ras epithelial cell line ( Supplementary  Figure 1d ), further supporting the notion that GD3S is necessary for TGF-β1-mediated induction of EMT. In the same manner, we found that the Snail-ER fusion protein, known to elicit EMT in the presence of 4-hydroxytamoxifen (4-OHT), 19 failed to confer an overt mesenchymal morphology, when GD3S expression was suppressed using shRNA (Figures 1f and g) or triptolide (Figures 1h and i). Accordingly, the induction of mesenchymal markers was delayed in these cells compared with control counterparts (Figures 1g and i). GD3S expression is high in cells that have undergone EMT as well as in triple-negative breast cancer (TNBC) cells when compared with cells with no EMT features (Supplementary Figure  1e ), which further underscores the links between GD3S and EMT properties. Collectively, these findings show that GD3S has a critical role in the maintenance of a mesenchymal phenotype in cells that have undergone EMT, as well as in the initiation of EMT in response to Snail, Twist and TGF-β1 in several model systems.
GD3S regulates invasion and motility of cancer cells
Passage of cells through an EMT not only promotes the acquisition of stem cell properties but is also known to confer concomitant migratory and invasive capabilities. [1] [2] [3] To test whether GD3S also regulates invasion, HMLE-Snail and MDA-MB-231 cells were cultured in a three-dimensional laminin-rich extracellular matrix matrigel (3D lrECM). As expected, vehicle-treated cells grew as highly invasive stellate structures (Figure 2a ). In sharp contrast, when we inhibited GD3S expression using triptolide, cells formed noninvasive multicellular structures (Figure 2a ) with the basement membrane intact as indicated by the presence of a continuous laminin V layer ( Figure 2b) . Moreover, the number of invasive acinus structures was significantly decreased in triptolide-treated lrECM cultures ( Figure 2c ). Similar results were obtained using MDA-MB-231 and HMLE-Snail cells expressing GD3S shRNA (Figures 2d and e ). We also employed MCF-10A cells known to form highly organized multicellular acini with an intact basement membrane 36 when cultured in 3D lrECM. However, in the presence of TGF-β1, MCF-10A cells form irregular invasive structures with a disrupted basement membrane. We found that concurrent exposure to triptolide considerably decreased TGF-β1-mediated invasive acinus formation and restored the integrity of the basement membrane when compared with vehicle-treated cells ( Figure 2f ). Finally, we also investigated the role of GD3S in cell migration using a scratch assay and found that inhibition of GD3S expression by triptolide ( Figure 2g ) or shRNA-mediated silencing ( Figure 2h ) reduced migration significantly in MDA-MB-231 and HMLE-Snail cells. Collectively, these findings show that GD3S is necessary for EMT as well as EMT-associated cell migration and invasive properties.
GD3S has an important role in metastasis
To examine the role of GD3S in the regulation of metastasis, we injected 4T1 cells (10 000) orthotopically into the mammary fat pad of syngeneic wild-type BALB/c mice. Once the mice had developed palpable tumors (Figure 3b ), we treated one set with triptolide-which inhibits GD3S, mesenchymal markers ( Figure 3a ) as well as GD2 expression in 4T1 cells ( Supplementary  Figure 2a )-and the other set with vehicle. The vehicle-treated mice developed lung metastasis as evidenced by strong luminescence in the lungs, whereas the triptolide-treated mice had significantly decreased luminescence in the lungs (Figure 3c ), indicating a reduced metastatic burden. To examine the role of GD3S in primary tumor formation and metastasis, we suppressed the expression of GD3S using shRNA in 4T1 cells. On confirming the knockdown ( Supplementary Figure 2b) , we injected 4T1 cells expressing control shRNA or GD3S shRNA (100 000) orthotopically into the mammary fat pad of syngeneic wild-type BALB/c mice. Remarkably, the GD3S-shRNA-expressing 4T1 cells yielded primary tumors that were significantly smaller in size compared with those generated by control-shRNA 4T1 cells, with the exception of one mouse ( Supplementary Figure 2c ). In addition, mice harboring the control-shRNA-expressing 4T1 cells developed large lung foci as evidenced by strong luminescence in the lungs, whereas the mice injected with GD3S-shRNA-expressing 4T1 cells exhibited significantly reduced luminescence in the lungs, consistent with a markedly reduced metastatic burden ( Supplementary Figure 2d ). To confirm that the reduction in lung nodules in mice harboring GD3S-shRNA-expressing 4T1 cells was not due to the reduction in primary tumor size, we investigated the role of GD3S in experimental metastasis. For this, we injected 0.5 × 10 6 red fluorescent protein (RFP)/luciferase-labeled MDA-MB-231 cells via the tail vein and subsequently treated the mice with either vehicle or triptolide for 6 weeks and analyzed for the presence of lung metastases using bioluminescent imaging. 24, 35 Whereas mice harboring vehicle-treated or control-shRNA-expressing MDA-MB--231 cells developed metastases (Figures 3d and e ), inhibition of GD3S using triptolide or shRNA significantly reduced the metastatic burden (Figures 3d and e ).
Using hematoxylin and eosin staining, we further confirmed the presence of large metastatic foci in the lungs of mice injected with control-shRNA-expressing MDA-MB-231 cells ( Figure 3f ) but not in mice injected with GD3S-shRNA-expressing MDA-MB-231 cells. Similarly, we only detected metastatic foci in the lungs of mice injected with MDA-MB-231 cells and subsequently treated with vehicle ( Figure 3f ) but not in mice injected with MDA-MB-231 cells and subsequently treated with triptolide. To distinguish whether GD3S regulates seeding of the cells to the lung or the expansion of seeded cells into macroscopic nodules, we performed immunofluorescence using anti-RFP on the lungs of mice injected with RFP-labeled MDA-MB-231 cells and treated with triptolide or RFP-labeled MDA-MB-231 cells expressing GD3S shRNA relative to their respective control mice. Although we observed extensive RFP staining indicative of the presence of large metastatic foci in the lungs of mice injected with control-shRNA-expressing MDA-MB-231 cells (Figure 3f , lower panel) or vehicle-treated MDA-MB-231 cells (Figure 3f , lower panel), we did not find colonies of RFP-positive cells in mice injected with GD3S-shRNA-expressing MDA-MB-231 cells or in the triptolide-treated mice harboring MDA-MB-231 cells. However, we did observe numerous RFPpositive single cells in the lungs of mice harboring MDA-MB-231 cells expressing GD3S shRNA or mice harboring MDA-MB-231 cells that were treated with triptolide, even though we did not observe lung nodules in these animals (Figure 3f , lower panel). These findings suggest that inhibition of GD3S does not compromise the seeding of cells to the lung but that it prevents the expansion of solitary disseminated tumor cells into macrometastatic lesions. Collectively, these data suggest that GD3S has an important role in regulating experimental metastasis.
To examine the role of GD3S in EMT in vivo, 4T1 tumor samples were processed for histology and immunostaining with GD2 as well as EMT markers (E-cadherin and vimentin). Using hematoxylin and eosin staining, we showed that inhibition of GD3S limits the invasion of the tumor into the surrounding tissue, rendering the tumor smooth at its edges with a histology characteristic of a noninvasive tumor ( Supplementary Figure 2e ). GD2 was increased at the invasive front of vehicle-treated tumors, whereas its expression was significantly reduced in triptolide-treated samples (Figure 3g ). E-cadherin was localized mostly to the membrane in triptolide-treated tumors (Figure 3h ), whereas staining was diffuse in vehicle-treated tumors. Conversely, vimentin expression was reduced ( Figure 3i ) in triptolide-treated 4T1 tumors compared with vehicle-treated samples. We also cultured MDA-MB-231 cells in 3D lrECM and exposed them to vehicle or triptolide. Acini were stained with laminin V as well as E-cadherin and N-cadherin. Inhibition of GD3S using triptolide inhibited N-cadherin expression ( Supplementary Figure 2f Collectively, these data show that inhibition of GD3S inhibits EMT in vitro and in vivo.
GD3S expression is regulated by NF-kB via FOXC2 and predicts poor clinical outcome
As the transcription factor FOXC2 is a downstream mediator of multiple different EMT signaling pathways, 37 we investigated directly regulates GD3S expression, we performed a chromatin immunoprecipitation assay using HMLE-Snail cells and found that FOXC2 preferentially binds to a region around 1.0 kb (−1.0 kb) upstream of the GD3S transcription start site (Figure 4d ), thus confirming that GD3S is transcriptionally regulated by FOXC2. Consistent with this, using an in vitro wound healing assay, we observed concomitant induction of both FOXC2 and GD3S at the wound site ( Supplementary Figure 2g) . As triptolide is known to inhibit GD3S, as well as NF-kB, 38 and NF-kB is known to regulate FOXC2, 39 we examined whether NF-kB could regulate GD3S via FOXC2. For this, we overexpressed an IkB super-repressor mutant (IKB-SR), known to inhibit NF-kB, in MDA-MB-231 and HMLE-Snail cells and found that the transcripts encoding GD3S and FOXC2 were reduced following overexpression of IKB-SR (Figures 4e and  f) . Furthermore, overexpression of FOXC2 in these IKB-SR expressing cells restored the expression of GD3S (Figures 4g and  h) . To further confirm that NF-kB and FOXC2 promote EMT in a GD3S-dependent manner, we overexpressed FOXC2 in GD3Ssilenced MDA-MB-231 cells and found that FOXC2 overexpression was not able to rescue either the EMT phenotype (Figure 4i ) or mammosphere formation (Figure 4j ) in the absence of GD3S. We also observed that overexpression of FOXC2 in MDA-MB-231 cells made them resistant to triptolide ( Supplementary Figures 3a and  e ). Collectively, these findings indicate that GD3S expression is regulated by NF-kB via FOXC2. Moreover, our bioinformatic analyses indicate that GD3S expression is high in claudin-low/ TNBCs (Figure 4k ) and that it correlates with poor patient survival (Figure 4l ).
GD3S regulates EMT and metastasis via activation of the c-Met signaling pathway
A recent study demonstrated that GD3S could enhance the proliferation and primary tumor growth of MDA-MB-231 cells via c-Met signaling. 28 To test whether GD3S expression correlates with the active and phosphorylatable form of c-Met, we analyzed the expression of phosphorylated c-Met across a panel of cell lines that have undergone EMT or exist in a mesenchymal state. Interestingly, we observed elevated phospho-c-Met (p-c-Met) in cells with EMT/ CSC properties (MDA-MB-231, SUM159, HMLE-Twist, -Snail and -TGF-β1) relative to their epithelial counterparts (MCF-10A, HMLEvector) even though all the cells expressed similar levels of total c-Met (Figure 5a ). Moreover, the pattern of c-Met phosphorylation strongly correlates with GD3S expression in all of the cells examined (Figure 5a ). To investigate whether GD3S expression is regulated by c-Met, we treated the cells expressing high GD3S and p-c-Met with SU11274, a c-Met inhibitor, and found that SU11274 is capable of reducing the expression of vimentin and increasing E-cadherin levels in MDA-MB-231 cells (Figure 5b ). Furthermore, SU11274 treatment substantially altered cell morphology causing increased clustering of cells into epithelial-like islands with prominent cell-cell contacts and reduced fibroblastic morphology (Figure 5c ). Finally, the sphere-forming capacity of these cells was also significantly reduced in the presence of SU11274 (Figure 5d ; Supplementary Figure 3f ). Although we observed loss of EMT/CSC functions in the presence of SU11274, we did not see any change in the expression of GD3S (Figure 5b ), suggesting that c-Met signaling functions downstream of GD3S.
To investigate whether GD3S regulates the activation of c-Met, we examined the presence of total c-Met as well as p-c-Met in MDA-MB-231 cells expressing GD3S shRNA compared with the control shRNA. Indeed, we found no change in total c-Met protein, but a significant decrease in active p-c-Met protein as well as its downstream signal mediator phospho-Akt (Figure 5e ), suggesting that GD3S regulates only the function of c-Met and not its expression.
To further examine whether activation of c-Met is sufficient to rescue the EMT/CSC properties in the absence of GD3S, we ectopically expressed a constitutively active form of c-Met (Tpr-Met) 29 in MDA-MB-231-shGD3S cells. Expression of Tpr-Met successfully restored the mesenchymal properties of these cells, even in the absence of GD3S, as evidenced by the acquisition of a mesenchymal-like morphology (Figure 5f ), elevated expression of vimentin ( Figure 5g ) and enhanced mammosphere-forming efficiency relative to the control vector-expressing cells (Figure 5h ). Next, we tested these cells for their ability to seed metastasis in vivo and found that mice injected with MDA-MB-231-shGD3S-Tpr-Met cells had significantly more lung metastases and reduced event-free survival compared with mice injected with MDA-MB-231-shGD3S-vector control cells (Figure 5i ).
DISCUSSION
Recent studies have clearly shown that the EMT process can promote the generation of CSCs, 19 which contribute to therapy resistance, tumor relapse and metastasis. 17, 18, 21, 22 To achieve an optimal clinical outcome, it is imperative: (1) to identify and target cancer cells with EMT/CSC properties, preexisting within a tumor, and (2) to prevent the de novo generation of CSCs via EMT during therapy. In this study, we report that GD3S is expressed at high levels in claudin-low/TNBC cell lines and patient tumors and that it is necessary for the acquisition and maintenance of EMT/CSC properties in multiple EMT models and claudin-low/TNBC cell lines. Furthermore, we demonstrate that inhibiting GD3S using shRNA or the small-molecule inhibitor triptolide could provide an effective strategy for the inhibition or reversal of the mesenchymal phenotype as well as metastasis in breast cancer.
Although GD2 synthase (GD2S) is directly responsible for GD2 biosynthesis, we previously found that GD3S, and not GD2S, is the rate-limiting enzyme in GD2 biosynthesis in cells that have undergone EMT as well as in mesenchymal-looking established breast cancer cell lines. 24 Moreover, the results presented here, along with our earlier findings, 24 clearly show that GD3S is functionally important both for mesenchymal properties as well as stem cell function. Although it is not clear how an enzyme involved in GD2 biosynthesis might regulate EMT, migration, invasion and metastasis, we speculate that GD2-the product of the GD3S biosynthetic pathway-may have a pivotal role in regulating these attributes either in an inter-or intracellular manner. Furthermore, we have established links between GD3S expression and activation of the c-Met signaling pathway. Moreover, our findings demonstrate that GD3S is important for the initiation of EMT in response to TGF-β1 as well as Snail and Twist. In addition, we have shown that NF-kB-known to respond to numerous inflammatory stimuli-can indirectly regulate GD3S transcription via the transcription factor FOXC2, a central mediator of multiple EMT programs. Thus, we speculate that GD3S may possibly have an important role in regulating EMT properties in response to a variety of EMT-promoting signals emanating from the tumor microenvironment, including tumor necrosis factor-α. With these considerations in mind, we propose that GD3S is likely to be an important therapeutic target for multiple EMT pathways operating in breast tumors.
Whereas inhibition of GD3S, using shRNA or triptolide, significantly reduced the metastatic burden in mice, it also reduced primary tumor growth. This suggests that GD3S and, possibly GD2, may be important for the expansion of tumor cells in vivo but not in vitro, because inhibition of GD3S did not affect cell proliferation rates in vitro. This is further evidenced on closer examination of the lungs from the mice injected with GD3S-shRNA-expressing cells or treated with triptolide, in which we observed numerous presumably dormant solitary tumor cells that failed to grow into macroscopic nodules. These data suggest that GD3S is important for the differentiation/expansion of cells after they have been seeded to the lung. Indeed, this fits well with our data that inhibition of GD3S inhibits c-Met signaling, which is important for the sustained proliferation and self-renewal properties of CSCs. 40 Our data indicate that GD3S expression is high in TNBCs and that its expression predicts poor clinical outcome, consistent with the notion that GD3S-mediated generation of GD2 enhances stem cell properties and may be responsible for the aggressive nature of these tumors and the poor clinical outcome observed. As GD3S is an enzyme and there is a small-molecule inhibitor available to inhibit its expression, we believe that our data attest to the potential efficacy of triptolide for the treatment of TNBCs and for eradicating CSC-enriched tumors. Our findings also suggest that targeting GD3S or c-Met signaling could be effective against tumor progression and metastasis. The findings presented here Week 1
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Week 9 establish GD3S as a novel functional gene specific to cells that have undergone EMT as well as mesenchymal-looking breast cancer cells and suggest that GD3S could serve as a novel therapeutic target for mesenchymal-appearing triple-negative claudin-low tumors. As targeted agents against GD3S, for example, triptolide, 41 are currently in clinical trials, we envisage that the optimal clinical outcome will only be achieved by using triptolide or c-Met inhibitor to eradicate CSCs in combination with standardof-care therapies that target the differentiated cells of the tumor bulk and that this approach will be effective for treating primary tumors and metastases.
MATERIALS AND METHODS

Cells and culture conditions
Immortalized HMLE and cells expressing empty vector (pWZL), Snail, Twist or an activated form of TGF-β1 were maintained as previously described. 10, 19, 37 Breast cancer cell lines SUM159 and MDA-MB-231 were cultured as described in Hollier et al. 37 For assays characterizing the resistance of cells to cytotoxic compounds, cells were seeded at a density of 8 × 10 3 cells/well of 96-well plates. After 24 h, medium was replaced with fresh growth medium (100 μl/well) containing the indicated concentrations of triptolide dissolved in dimethyl sulfoxide (DMSO). Control cells were treated with DMSO. Cell viability was assessed using the CellTiter96 Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA). The mouse mammary tumor 4T1 cells were cultured as described. 10 
Plasmids and viral transduction
The method used for the production of lentiviruses and amphotropic retroviruses as well as the transduction of target cells was previously described. 42 Cat#9272) . Following incubation with horseradish peroxidase-conjugated secondary species-specific antibodies, immunoreactive proteins were detected using chemiluminescence (ECL Plus, GE Healthcare, Barrington, IL, USA). Immunofluorescence staining of cells was performed as previously described 37 and formalin-fixed paraffin-embedded tissue sections were stained as described 43 using the above-mentioned antibodies along with GD2 (BD, clone 14G2a).
Cell culture and chromatin immunoprecipitation assays
Fluorescence-activated cell sorting, 24 chromatin immunoprecipitation, 37 3D lrECM on-top cultures 36, 37 and mammosphere assays 19 were conducted as previously described.
Animal studies
Non-obese diabetic/severe combined immunodeficient (NOD/SCID) and BALB/C mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and all mouse procedures were approved by the Animal Care and Use Committees of the University of Texas MD Anderson Cancer Center and performed in accordance with Institutional policies. To assess the experimental metastatic potential of cells, 5 × 10 5 MDA-MB-231 control-shRNA and GD3S-shRNA cells labeled with RFP-firefly luciferase were injected into NOD/SCID mice via the tail vein. Mice were assessed weekly for metastasis via the intraperitoneal injection of D-Luciferin (Caliper LifeSciences, Hopkinton, MA, USA). After allowing 10 min, in vivo bioluminescence was assessed using the IVIS imaging system 200 series (Xenogen Corporation, PerkinElmer, Waltham, MA, USA). Mice were monitored for lung metastasis and euthanized after 6 weeks, at which time the lungs were surgically removed and fixed using Bouin's fluid and the number of lung tumor nodules was counted using a dissection microscope. Lungs were further subjected to hematoxylin and eosin staining and stained for RFP to ascertain the presence of MDA-MB-231 cells. To assess the inhibitory effect of triptolide on experimental metastasis, 0.5 × 10 6 MDA-MB-231 cells labeled with RFP-firefly luciferase were injected into NOD/ SCID mice via tail vein injection. Thereafter, triptolide (0.15 mg/kg/day) was administered intraperitoneally on a daily basis. Mice were euthanized after 6 weeks, and lung metastatic nodules were quantified as detailed above.
To examine the role of GD3S in tumor formation and spontaneous metastasis, 0.1 × 10 6 4T1-control-shRNA and 4T1-GD3S-shRNA cells were injected orthotopically into the mammary fat pad of BALB/c mice. Mice were assessed weekly for tumor size and metastasis via the intraperitoneal injection of D-Luciferin. Tumors and lung metastases were measured after euthanizing the mice at 3 weeks. To confirm the role of GD3S in the progression of metastasis, 10 000 4T1 cells were injected into BALB/c mice and once palpable tumors had formed, one set of mice was treated with triptolide and the other set was treated with vehicle. Tumors and lung metastases were measured after euthanizing the mice at 5 weeks. To ascertain the role of Tpr-Met in experimental metastasis in the absence of GD3S, 0.5 × 10 6 MDA-MB-231-GD3S-shRNA-vector and MDA-MB-231-GD3S-shRNA-Tpr-Met cells, labeled with RFP-firefly luciferase, were injected into NOD/SCID mice via tail vein injection. Mice were assessed weekly for metastasis via the intraperitoneal injection of D-Luciferin. The Kaplan-Meier survival curve was generated.
Quantitative reverse-transcription PCR
Total RNA was isolated using the RNeasy Plus kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. All quantitative reversetranscription PCR experiments were run in triplicate and a mean value was used for the determination of mRNA levels. Relative quantification of the mRNA levels was performed using the comparative C t method with glyceraldehyde 3-phosphate dehydrogenase as the reference gene and with the formula 2 − ΔΔCt .
Scratch assays
Cells (~3 × 10 5 cells/well) were seeded in culture dishes and allowed to adhere for 8-10 h in medium containing 0.5% fetal bovine serum in the case of MDA-MB-231 and only medium without fetal bovine serum in the case of HMLE-Snail cells. A scratch was done using a sterile pipette tip and the dish was filled with fresh medium. Wound closure was monitored and recorded over time.
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